MAX Chat
Company Analysis Innovent Biologics, Inc.
1. Summary
Advantages
- The stock's return over the last year (166.86%) is higher than the sector average (-28.42%).
Disadvantages
- Price (12.9 $) is higher than fair price (9.53 $)
- Dividends (0%) are below the sector average (1.61%).
- Current debt level 13.11% has increased over 5 years from 11.63%.
- The company's current efficiency (ROE=-0.738%) is lower than the sector average (ROE=14.32%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Innovent Biologics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 1.6% | -9.4% | 0% |
| 90 days | 32.5% | -30.3% | 7.6% |
| 1 year | 166.9% | -28.4% | 18.9% |
IVBXF vs Sector: Innovent Biologics, Inc. has outperformed the "Healthcare" sector by 195.28% over the past year.
IVBXF vs Market: Innovent Biologics, Inc. has outperformed the market by 147.95% over the past year.
Stable price: IVBXF is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: IVBXF with weekly volatility of 3.21% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (12.9 $) is higher than the fair price (9.53 $).
Price is higher than fair: The current price (12.9 $) is 26.1% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (-192.62) is lower than that of the sector as a whole (46.56).
P/E vs Market: The company's P/E (-192.62) is lower than that of the market as a whole (46.13).
4.3. P/BV
P/BV vs Sector: The company's P/BV (4.08) is lower than that of the sector as a whole (5.34).
P/BV vs Market: The company's P/BV (4.08) is lower than that of the market as a whole (4.36).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (5.67) is higher than that of the sector as a whole (4.29).
P/S vs Market: The company's P/S indicator (5.67) is lower than that of the market as a whole (12.96).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-101.57) is lower than that of the sector as a whole (17.57).
EV/Ebitda vs Market: The company's EV/Ebitda (-101.57) is lower than that of the market as a whole (27.25).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -18.1% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-18.1%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-1.77%).
5.4. ROE
ROE vs Sector: The company's ROE (-0.738%) is lower than that of the sector as a whole (14.32%).
ROE vs Market: The company's ROE (-0.738%) is lower than that of the market as a whole (52.17%).
5.5. ROA
ROA vs Sector: The company's ROA (-0.4482%) is lower than that of the sector as a whole (7.27%).
ROA vs Market: The company's ROA (-0.4482%) is lower than that of the market as a whole (36.33%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-28.1%) is lower than that of the sector as a whole (14.12%).
ROIC vs Market: The company's ROIC (-28.1%) is lower than that of the market as a whole (10.84%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.61%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
